AC Immune's Parkinson's Candidate ACI-7104 Secures FDA Fast Track and IND Clearance

summarizeSummary

AC Immune's Parkinson's immunotherapy ACI-7104 has received FDA Fast Track designation and IND clearance, paving the way for U.S. clinical sites and closer regulatory collaboration ahead of pivotal Phase 2 data in H2 2026.

check_boxKey Events · Product Development and Regulatory · ACIU

• FDA Fast Track Designation

  ACI-7104, an anti-alpha-synuclein active immunotherapy for early-stage Parkinson's disease, has been granted FDA Fast Track designation, reflecting the positive interim Phase 2 safety and immunogenicity data.

• IND Clearance for U.S. Sites

  The FDA cleared the Investigational New Drug application, allowing the ongoing Phase 2 VacSYn trial to expand to U.S. clinical sites.

• Regulatory Milestone De-Risks Program

  Fast Track enables more frequent FDA interactions, potential priority review, and a rolling submission, improving the regulatory path for this wholly owned asset.

• Phase 2 Data Readout on Track

  Final Part 1 week-100 results from the VacSYn trial remain on schedule for announcement in H2 2026, a near-term catalyst.

auto_awesomeAnalysis · ACIU · Life Sciences

Securing FDA Fast Track designation and IND clearance for ACI-7104 marks two major regulatory wins that significantly de-risk the wholly owned Parkinson's program. Fast Track opens the door to closer FDA collaboration, potential priority review, and a rolling submission, while the IND clearance lets U.S. clinical sites join the ongoing Phase 2 VacSYn trial. These milestones build on positive interim safety and immunogenicity data and arrive ahead of the full Part 1 week-100 results expected in H2 2026. For a company with a market cap around $232 million, advancing a wholly owned asset through key FDA gates not only strengthens the pipeline but could also attract partnership interest or non-dilutive funding.